KetSet Trial: Psychedelic vs Biomedical Framing of Ketamine in Sweden

KetSet Trial Directly Tests Framing Effects in Ketamine Therapy

The KetSet study is a randomized controlled superiority trial at Skaraborg Hospital, Sweden, designed to determine whether the psychological framing of intravenous ketamine treatment influences antidepressant outcomes in adults with treatment-resistant depression (TRD). Registered at ClinicalTrials.gov (NCT07824973), KetSet randomizes 120 patients already prescribed ketamine to receive either a psychedelic or biomedical framing of their treatment, while keeping the drug regimen identical in both groups.

All participants receive six intravenous infusions of ketamine (0.5 mg/kg over 40 minutes) across four weeks. The primary outcome is the change in Montgomery–Åsberg Depression Rating Scale (MADRS) scores from baseline to 12 weeks, assessed by blinded raters. Secondary outcomes include symptom trajectory, response and remission rates, adverse events, discontinuation, quality of life, psychological well-being, therapeutic alliance, and subjective experiences. An embedded mixed-methods component uses interviews and questionnaires to explore how patients make sense of their ketamine experiences.

Mechanisms: Framing, Set and Setting, and Subjective Experience

Psychological framing refers to how patients are prepared for, supported during, and debriefed after ketamine infusions. The psychedelic framing emphasizes openness to subjective experiences, use of music and eyeshades, and therapeutic support, drawing on protocols from classic psychedelic research. The biomedical framing focuses on ketamine's pharmacological action, symptom management, and coping with potential adverse effects, mirroring typical biomedical care.

Research on classic psychedelics suggests that subjective experiences—such as dissociation, altered perception, and emotional breakthroughs—may correlate with antidepressant effects, but causality remains unproven. By manipulating framing and support while holding the drug constant, KetSet aims to isolate the contribution of psychological context to clinical outcomes. This approach addresses a real-world dilemma: should clinics adopt psychedelic therapy elements, or is standard biomedical care sufficient?

Policy and Clinical Implications: Toward Evidence-Based Ketamine Practice

The KetSet trial could reshape clinical standards for ketamine therapy if the psychedelic framing yields superior outcomes. Clinics may need to adapt protocols, invest in training for psychological support, and reconsider the role of music, eyeshades, and preparation. Health insurers and regulators could use these findings to inform reimbursement models and guidelines, distinguishing between simple drug administration and more resource-intensive psychedelic-assisted protocols.

Notably, the trial's embedded health economics analysis will provide data on cost-effectiveness, a key factor for public health systems and private payers. If psychedelic framing improves outcomes without excessive added cost, it may become the new standard. Conversely, if no difference is found, resources could be redirected to other aspects of care. The mixed-methods component offers a rare opportunity to understand not just whether, but how, framing shapes outcomes—an insight often missing from drug-centric trials.

Risks, Unknowns, and Limitations

While the KetSet trial is rigorously designed, several uncertainties remain. The open-label design means patients know their treatment framing, which could amplify expectancy effects. The single-center setting at Skaraborg Hospital may limit generalizability to other health systems or cultural contexts. Importantly, recruitment has not yet commenced as of the trial's OSF registration, so timelines for results are uncertain.

Safety remains a priority: both arms monitor for adverse events and discontinuation. However, the trial will not address long-term relapse rates or optimal maintenance strategies, which are pressing issues in ketamine therapy. There is also a risk that positive findings could be over-interpreted as supporting broad psychedelic therapy adoption, when in fact nuanced, context-sensitive implementation will be required.

Looking Ahead: Research and Practice After KetSet

The KetSet trial represents a pivotal test of the "set and setting" hypothesis in a modern clinical context, with direct implications for the future of ketamine and psychedelic-assisted therapies. Its results could inform not only Swedish practice but also international guidelines, training standards, and health policy. For researchers, the trial's mixed-methods approach and focus on patient experience set a new benchmark for evaluating complex interventions.

One non-obvious implication is that, regardless of outcome, the trial will clarify whether investments in psychological support for ketamine therapy are justified by measurable benefits. This evidence will be crucial as clinics, payers, and regulators seek to balance patient-centered care with scalability and cost control. As the field awaits KetSet's findings, stakeholders should prepare for the possibility that the "how" of ketamine administration may matter as much as the "what."

Authored by Dr. Erik Sandström, MD, PhD. Reviewed by Dr. Johanna Nilsson, MD, on 2026-10-21. Research based on primary trial registration and OSF protocol from the KetSet study team.